Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Ends Certiva Agreement In U.S.; NAVA Focuses on NeisVac-C for U.K.

Executive Summary

Abbott has terminated its agreement with North American Vaccine to market its combination diphtheria, tetanus and acellular pertussis vaccine Certiva to private physicians in the U.S.

You may also be interested in...



Baxter Acquisition Of NAVA Hinges On Approval of NeisVac-C in U.K.

Baxter's acquisition of North American Vaccine is contingent upon the U.K. approval of NAVA's group C meningococcal conjugate vaccine NeisVac-C.

Baxter Acquisition Of NAVA Hinges On Approval of NeisVac-C in U.K.

Baxter's acquisition of North American Vaccine is contingent upon the U.K. approval of NAVA's group C meningococcal conjugate vaccine NeisVac-C.

Meningococcal Conjugate Vaccine Studies May Use Immunologic Correlates

Immunologic correlates may be used to predict protective efficacy of meningococcal conjugate vaccines, FDA's Vaccines and Related Biological Products Advisory Committee agreed at a Sept. 15 meeting in Bethesda, Md.

Related Content

UsernamePublicRestriction

Register

PS034941

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel